A concise review on analytical profile of naproxen

Pritam’s Jain

Associate Professor, R. C. Patel institute of pharmaceutical education and research, Shirpur, Maharashtra, India

Abstract
Naproxen (NAP) is a Non-steroidal anti-inflammatory drugs (NSAID) used in the treatment of pain or inflammation caused by situations such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps. Nap is available in isolated dosage from with various similar anti-inflammatory drugs, esomeprazole, pantoprazole, paracetamol, ranitidine, sumatriptan and ibuprofen. The present exploration evaluates the various method for analysing of NAP in bulk drugs and formulated products. A summarizing review characterizes the gathering and conversation of about more than 62 analytical methods which includes HPLC, HPTLC, UV-Spectrophotometry, capillary electrophoresis, electrochemical methods. HPLC technique are provided in Table03 and Table 04 for NAP alone and combination, including parameters such as matrix, stationary phase, mobile phase, wavelength detection etc. and HPTLC methods are reported in Table 05 with parameters like stationary phase, mobile phase combination, Rf etc. Method of UV-Spectrophotometry applied for examination of NAP in biological mediums, bulk sample and in various dosage formulation. Spectrometric methods for NAP alone and in mixture are given in Table 08 which includes parameters like λ max, solvent, matrix etc.

Keywords: Naproxen, HPLC, HPTLC, UV-Spectrophotometric, LC-MS/MS.

Introduction
Naproxen is a structurally [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid] action has non-steroidal anti-inflammatory medicine that shows both antipyretic and analgesic behaviour.

The mechanism action of naproxen, similar to that of other NSAIDs, has believed to be related with Cyclooxygenase activity inhibition. COX-1 inhibition should be complementary to gastrointestinal and renal toxicity while COX-2 inhibition is anti-inflammatory.

Similar to added NSAIDS naproxen is capable of creating troubles in the gastrointestinal tract naproxen is practically insoluble in water, soluble in ethanol 96 percent and pKa in methanol 4.2. Naproxen is generally metabolized to 6-0-desmethyl naproxen and mutally parent and metabolized do not produce metabolizing enzymes. The practically observed incurable exclusion half-life is almost 15 hours. Naproxen is normally used for the reduction of fever, pain also inflammation and stiffness caused by in conditions including of osteoarthritis, migraine, rheumatoid arthritis, psoriatic arthritis, kidney stone, gout, kidney stone, menstrual cramps, ankylosing spondylitis, tendinitis and bursitis.

Mechanism of action
The mainly mechanism action of naproxen is its inhibition of production prostaglandin of by binding reversibly to cyclooxygenase. This have first enzyme in the arachidonic acid cascade that results in the synthesis of prostaglandins. By lowering the levels of these abundant substances, naproxen affects pain, inflammation, fever, uterine contractility, platelet aggregation, and vasoactivity, all of which are mediated by prostaglandins and related thromboxanes and prostacyclin. All non-steroidal anti-inflammatory preparations appear to act same by blocking the cyclooxygenase stage in the cascade.

Pharmacokinetic data

Bioavailability
Naproxen is one of the fastly and completely produced in the GI tract with an in vivo bioavailability of 95%. Although naproxen itself is good absorbed, the sodium salt form is more speedily absorbed resulting in greater

*Corresponding Author: Pritam’s Jain, Associate Professor, R. C. Patel institute of pharmaceutical education and research, Shirpur, Maharashtra, India
Email: pritash79@yahoo.com
http://doi.org/10.18231/j.ijcaap.2019.016
maximum plasma concentration at specified dose. Food causes a minor decrease in absorption rate.

**Protein binding**
Therapeutic levels of Naproxen >99% albumin-bound.

**Metabolism**
Naproxen and Parent as well as and metabolites do not cause enzyme metabolizer. Naproxen is widely metabolized to 6-O-desmethyl

**Half-life**
The practically observed elimination of half-life is approximately 15 hours.

**Excretion**
0.13 mL/kg clearance of naproxen. Almost 95% of the naproxen from any dose is excreted in the urine, mostly as naproxen (Less than 4%), 6-O-desmethyl naproxen (less than 1%) or their conjugates (66%-92%).

**Clinicaluse**
Naproxen if used to relieve pain from various circumstances, including headaches, muscle aches, tendonitis, dental suffering, and cramps of menstruation. It also decreases arthritis, bursitis, and gout assaults pain, inflammation, and joint stiffness.

**Adverse effects**
Naproxen was correlated with the lowest general cardio vascular risk of all the NSAIDs assessed. As with other NSAIDs, naproxen may trigger gastrointestinal issues such as heartburn, constipation, diarrhea, ulcers, and swelling in the stomach. It may interfere with and decrease the efficacy of SSRI antidepressants.6

**Metabolite**
The 6-O-desmethylated metabolite (DM-naproxen) is unchanged excreted and combined with sulfate and glucuronic acid The 6-O-desmethylated metabolite (DM-naproxen) is excreted unaffected as well as combination with glucuronic acid and sulphate.7

**Analytical accounts on naproxen**
The general literature survey discovered, several analytical method viz UV/Visible- Spectrophotometry, Spectrofluorimetry, HPLC, HPTLC and LC-MS for the resolve of NAP in bulk and pharmaceutical product. The recorded methods describe the determination of naproxen in different dosage forms as single component and in mixture with esomeprazole, domperidone, sumatriptan succinate, pantoprazole, rabeprazole, pseudoephedrine, paracetamol, ranitidine hydrochloride, diphenhydramine hydrochloride. Fig. 4 shows different analytical methods implemented for assessment of naproxen.8

**Analytical method for Naproxen**

| Table 1: Dosage forms, route of administration and recommended dose of NAP |
|----------------------------------|------------------|------------------|
| **Dosage forms** | **Route of administration** | **Indication/dose** |
| Tablet and suspension | Usual Adult Dose of Ankylosing Spondylitis- 250 mg to 500 mg (naproxen) or 275 mg to 550 mg (naproxen sodium) twice daily orally |
| Tablet and suspension | Usual Adult Dose of Rheumatoid Arthritis-250 mg to 500 mg (naproxen) or 275 mg to 550 mg (naproxen sodium) twice daily orally |
| Tablet | Usual Adult Dose for Acute Gout-750 mg |
Pharmacopeial status

IP portrayed HPLC assay technique consuming a stainless steel 25 cm x 4.6 mm, packed with silica gel π-acceptor/π-donor for chiral separations (5μm), as a static phase and mobile phase comprised of 5 volumes of a glacial acetic acid, 50 volume of acetonitrile, 100 volume of 2-propanol and 845 volume of hexane, keeping the flow rate of 2 mL/min. Column effluent was scrutinized on 263 nm, and injection volume set at 20 μl.⁹

Accounts on bio-analytical method for estimation of naproxen

Bio-analysis is a sub-discipline of analytical chemistry casing the quantitative dimension of xenobiotics and biotic (proteins, macromolecules, DNA, metabolites, molecule of drugs,) in biological systems.¹⁰

Literature survey exposed that HPLC is predominantly used for the bio-analysis of Naproxen

S. Ashutosh Kumar et al (2014) was studied the bioanalytical RP-HPLC technique for simultaneous purpose of ESOM and NAP in human plasma was established and validated as per US-FDA guidelines, by consuming symmetry C18 (250 mm×4.6mm, 5 250 mm, 5 μm) XTerra column and potassium dihydrogen phosphate and acetonitrile with mobile phase portion of 60:40 v/v at a pour rate of 1.0ml/min. 1.0-6.0 μg/ml concentration range was selected for ESOM and NAP 25.0-150.0 μg/ml, and 0.999 correlation coefficient of both drugs respectively ESOM and NAP. The assay of allowable measurement of ESOM and NAP was found to be 0.04μg/ml both drugs. The average recovery for the drug ESOM and NAP was found to be 98.97-99.84 and 99.80-100.95.¹¹

Bilal Yilmaz et al. (2013) recognized a validated simple HPLC technique has been recognized for the resolution of NAP in human plasma. The detection was accomplished on an Ace C18 column using UV-Detection. The mobile phase having of 20mm phosphate buffer (pH7) containing 0.1% trifluoroacetic acid: acetonitrile (65:35) v/v and The linearity was reliable in series of 0.10 and 5.0 mg/ml. precision (intra-day, inter-day)correctness morals for NAP in plasma were less than 4.84, and accuracy (reasonable error) was better than 3.67%.

Nap’s extraction percent retrieval trials since human plasma were discovered to be 91.0 and 98.9%. The LOD and LOQ were discovered to be 0.03 and 0.10 mg/ml, respectively. This assay was also helpful in regulating NAP pharmacokinetic variables in six energetic Turkish volunteers who needed to remain given 220 mg of NAP.¹²

Table 2: Bio-Analytical NAP technique

| S. No. | Drug                                      | Sample Matrix | Method       | Column | Detection | Internal Standard | Ref |
|--------|-------------------------------------------|---------------|--------------|--------|-----------|-------------------|-----|
| 1.     | NAP                                       | Human plasma  | HPLC         | C18    | -         | Ibuprofen         | 12  |
| 2.     | NAP                                       | Human plasma  | HPLC         | C18    | 254nm     | ACN (Human Plasma)| 13  |
| 3.     | NAP, IBFN and PARA                        | Human plasma  | HPLC-UV      | Zorbax SB-C18 | 232nm     | Fenoprofen        | 14  |
| 4.     | NAP and ESOM                              | Human plasma  | LC-MS/MS     | XBridge C18 | -         | Ibuprofen         | 15  |
| 5.     | Atenolol, Rosuvastatin, Spironolactone and NAP Sodium | Human plasma | RP-HPLC      | C18    | 235nm     | Flurbiprofen      | 16  |
| 6.     | NAP                                       | Human Urine   | HPLC         | C18    | -         | -                 | 17  |
| 7.     | ESOM and NAP                              | Human plasma  | RP-HPLC      | C18    | 285nm     | -                 | 18  |
| 8.     | NAP                                       | Human plasma  | LC-MS/MS     | -      | -         | Ketoprofen        | 19  |
| 9.     | NAP                                       | Human plasma  | LC-MS/MS     | C18    | -         | Zidovudine        | 20  |
| 10.    | NAP and BPB                               | Human Serum   | Spectrophotometry | - | 432 nm | -                 | 21  |
**Table 3: HPLC Method for Naproxen (NAP)**

| S. No | Drug    | Method      | Matrix       | Column | Mobile Phase                                      | Flow rate | Detector       | Rt     | Ref |
|-------|---------|-------------|--------------|--------|--------------------------------------------------|-----------|----------------|--------|-----|
| 1     | NAP     | RP-HPLC     | Bulk         | C18    | Phosphate Buffer and Methanol 40:60 (v/v),        | 1.3 ml/min | UV-Detector   | NAP-5.82 | 24  |
| 2     | NAP     | HPLC        | Tablet       | -      | Acetonitrile and 10 mm Ammonium acetate buffer pH 3.8 in ratio 550:450 v/v (pH 3.8 adjusted with acetic acid) | 1.0 ml/min | -              | 5.9 ± 0.01 | 25  |
| 3     | NAP     | RP-HPLC     | Dosage form  | C18    | Acetonitrile: 0.5 M potassium dihydrogen phosphate buffer pH 2.5 adjusted with orthophosphoric acid: tetrahydrofuran (45:53:2 v/v/v). | 1.0 ml/min | UV-Detector | 3.25 min. | 26  |
| 4     | NAP     | RP-HPLC     | Bulk and Tablet | C18    | Ammonium acetate Buffer: Methanol 40:60 (v/v)      | 1.0 ml/min | UV-Detector | 3.063   | 27  |
| 5     | NAP     | UHPLC       | Bulk         | C18    | -                                                 | 1.0 ml/min | UV-Detector | -       | 28  |

**Table 4: HPLC methods for analysis of Naproxen in combination**

| S. No | Drug and Drug | Method      | Matrix | Column | Mobile Phase                                      | Flow rate | Detector       | Rt     | Ref |
|-------|----------------|-------------|--------|--------|--------------------------------------------------|-----------|----------------|--------|-----|
| 1     | SUMA and NAP  | RP-HPLC     | Tablet | C18    | ACN: Water (60:40) and 0.05% v/v.                 | 1 ml/min  | PDA Detector   | SUMA 2.26 | 29  |
| 2     | NAP and ESOM  | HPLC        | C18    |        | Phosphate buffer (pH 6.1) and acetonitrile in ratio of 40:60, v/v. | 1.5 ml/min | UV Detector | NAP 1.72, ESOM 2.29 | 30  |
| 3     | DOM and NAP   | RP-HPLC     | C18    |        | Phosphate buffer (pH adjusted to 3.00 with sodium hydroxide): methanol in the ratio 30:70 (v/v) | 1.0 ml/min | UV Detector | DOM-3.17, NAP-5.42 | 31  |
| 4     | NAP and NAP   | RP-HPLC     | -      | C18    | Phosphate buffer (pH 6.5)                         | 1.0 ml/min | UV Detector | DOM-5.82 | 32  |
| Sample Type | Mobile Phase | Purity Assay | Concentration | Detector | Compound |
|-------------|--------------|-------------|---------------|----------|-----------|
| DOM         | HPLC         | adjusted with orthophosphoric acid and acetonitrile in the ratio of 50:50 (v/v) | 1.0 ml/min | UV-Detector | ESOM-2.425 NAP-4.27 |
| NAP and ESOM | RP-HPLC      | -           | -             | -        | NAP-3.425 NAP-4.352 |
| NAP and PAN | RP-HPLC      | Capsule C18 | Water: Methanol in The ratio of 55:45 (v/v) | 1.0 ml/min | UV-Detector | SUM-2.380 NAP-3.480 |
| NAP and PAN | RP-HPLC      | Capsule C18 | Phosphate buffers (K2HPO4, KH2PO4) (pH 6.5) Acetonitrile (55:45 v/v) | 1.0 ml/min | - | NAP-3.375 PAN-4.907 |
| NAP and PAN | RP-HPLC      | Capsule C18 | Methanol: phosphate buffer (5.4) in the ratio of 70:30 (v/v) | 1.0 ml/min | PDF-Detector | NAP-3.33 PENTO-1.90 |
| ESM and NAP | RP-HPLC      | C18         | Acetonitrile: Phosphate buffer (pH 7.0) in the ratio of 50:50 (v/v) | 0.5 ml/min | PDF-Detector | ESO-3.33 PENTO-1.90 |
| NAP and ESOM | HPLC         | C18         | Buffer: Acetonitrile: Methanol = 50:40;10 add 0.1% v/v Triethylamine in above mixture and finally adjust with glacial acetic acid to a pH 7.0. | 1.0 ml/min | UV-Detector | - |
| NAP and ESOM | RP-HPLC      | Tablet C18  | Buffer, Acetonitrile and Methanol in the ratio of (70:20:10) (v/v/v) | 1.5 ml/min | UV-Detector | NAP-3.352 ESO-6.112 |
| NAP and RAB | RP-HPLC      | Bulk C18    | Sodium dihydrogen Buffer: Acetonitrile in the ratio of 70:30 (v/v/v) | 1.0 ml/min | UV-Detector | NAP-3.33±0.0.27 RAB-7.61±0.0.43 |
| NAP and SUMA | RP-HPLC     | Bulk and Dosage form C8 | Buffer: Acetonitrile In the ratio of 50:50 (v/v/v) | 0.7 ml/min | UV-Detector | NAP-2.249 SUM-5.875 |
| NAP and PEPH | HPLC         | -           | Spherisorb Cyano | Water: acetonitrile–Methanol: triethylamine mixture in the ratio of 850:75:75:5 (v/v/v) | 0.5 ml/min | UV-Detector | NAP-Na 1.11 PSEH-0.39 |
| SUMA and NAP | RP-HPLC      | Bulk and Dosage form C18 | Acetonitrile: Methanol: phosphate buffer in the ratio of 50:10:40 (v/v/v) | 1.0 ml/min | - | NAP-4.037 SUM-2.813 |
| SUMA and NAP | UPLC         | -           | Acetonitrile: Water In the ratio of 90:10 (v/v/v) | 1.0 ml/min | UV-Detector | SUM-1.7 NAP-2.7 |
| PARA and NAP | RP-HPLC      | Tablet C18  | Water: Acetonitrile in the ratio of 87:13 (v/v/v) | 1.0 ml/min | UV-Detector | PAPA-3.005 NAP-7.402 |
| ESOM and NAP | RP-HPLC      | Bulk and Tablet C18 | Phosphate buffer (pH 3) and Acetonitrile | 1.0 ml/min | DAD and UV Detector | ESO-2.105 |
High performance thin layer chromatography (HPTLC)

Six easy HPTLC techniques were studied for simultaneous NAP estimation in mixed dosage from with SUMA, PAN, DOM and DIPH. Table 5 shows the overview of the reported HPTLC techniques.

Riddhi Gondalia et al. (2011) created and validated a straightforward mixed dosage technique for NAP and SUMA, a conventional NAP and SUMA solution for percolated silica gel 60F 254, and a mobile phase for methanol growth: distilled water: formic acid ratio of 0.5:7.5:0.1 (v/v/v). The accuracy and precision of the suggested technique were analyzed by the recovery study and the % recovery for SUMA was 99.255 and 99.0.3% respectively, and behind development, plates were observed under UV light. The detector response for NAP sodium and SUMA succinate was linearity in the range of 200-1200 ng / spot and 100-1000 ng / spot.

Shubhangi M. Pawar (2010), Investigation of a easy, accurate and precise high-performance thin-layer chromatographic technique for simultaneously quantify action of DOM-S and NAP-S as bulk drug and in tablet dosage form. The stationary phase was carried out on aluminum plates pre-coated with silica gel 60F 254, and mobile phase was toluene: methanol: acetone (8: 2: 2, v/v/v), and Rf value was found to be 0.44±0.02 and 0.5 ± 0.02 for DOM-S and NAP-S, respectively. The densitometric scanning was done at 266 nm. The linearity range was chosen by 20–140 ng. spot-1 for NAP and 500-3500 ng. spot-1 for NAP., precision (intra-day RSD0.4–1.01% and inter-day RSD 0.316–0.876% for DOM, and intra-day RSD 0.488–1.329% and inter-day RSD 0.450–1.026% for NAP), and accuracy (98.38 ± 0.55% for DOM and 98.64 ± 0.49% for NAP), specificity, in accordance with ICH guidelines.

Table 5: HPTLC Method for determination of Naproxen

| S. No | Drugs | Matrix | Stationary phase Plates | Mobile phase composition | Detection (nm) | Linearity | Rf | Ref |
|------|-------|-------|-------------------------|--------------------------|---------------|-----------|----|-----|
| 1    | NAP and SUMA | Dosage form | Silica gel 60F254 | Methanol: distilled water: formic acid in the capacity ratio of 0.5:7.5:0.1 (v/v/v), | 230 nm | (200-1200 ng/spot) NAP (100-1000 ng/spot) SUMA | - | 53 |
| 2    | DOM and NAP | Bulk | Silica gel 60 F254 | Toluene: Methanol: acetone (8: 2: 2, v/v/v), | 266 nm | 20-140 ng.spot -DOM 500-3500 ng.spot- | - | 54 |
**Spectrophotometry methods**

Till the date, the UV-Spectrophotometry methods for determination of NAP alone and in one or more dosage forms. The Spectrophotometry methods have been investigated analysis of NAP in tablets. The details Spectrophotometry and Spectrophotometry designating the basic principle, sample matrix, \( \lambda_{\text{max}} \) and solvent and linearity range are concise in Table 8.

**Methods for analysis of NAP as a single component**

*Senthil Rajan Dharmalingam et al. (2013)* The simple, delicate and accurate UV-Spectrophotometric technique for defining NAP in bulk and semisolid formulation was Dignified at 31 nm. The linearity range for NAP was discovered to be 10-60 μg/ml, and the system was validated for various parameters such as accuracy, accuracy and specificity as per guidelines (ICH). Comparative usual deviation and % recovery standards have been discovered to be satisfactory, representative that the suggested method is accurate and precise and can be used later in bulk and semisolid pharmaceutical formulation for repetitive NAP investigation.

**Methods for analysis of NAP in combined dosage form with other drugs**

Along with many anti-inflammatory, histamine and gastrointestinal agents, NAP is applicable. Few UV-spectrophotometry methods were reported for the simultaneous determination of NAP in dosage forms and simple, fast, precise, accurate and economical methods were developed for the evaluation of NAP and PANTO, DOM, PARA, RAN in tablet dosage form.

*Asha Patel et al. (2014)* For the simultaneous evaluation of NAP and PARA in pharmaceutical dosage form, the easy, Q-absorbance ratio UV-spectrophotometric technique was researched and validated. The chemicals used were NaOH 0.1N. The first scheme of working simultaneous equation solving based on the identification of absorbance at two wavelengths, 257.00 nm (\( \lambda_{\text{max}} \) for PARA) and 234.00 nm (Isoabsorptive point) were specific to the approximation of PARA and NAP for the technique of Q-absorbance proportion. To select the isoabsorbent point for evaluation, the overlay spectrum of NAP and PARA drugs was used. The chemicals used were NaOH 0.1N. The first operating system to solve simultaneous equation based on the detection of absorbance at two wavelengths, 257.00 nm (\( \lambda_{\text{max}} \) for PARA) and 234.00 nm. Linearity of the preferred technique for paracetamol was 2.5-5.0 μg/ml and for naproxen was 1.5-3.0 μg/ml. The recovery study was found to be corresponding to 97.91% (PCM) and 98.64% (NAX). The predicted scheme was a correct, selective and accurate in bulk formulation for simultaneous evaluation of NAP and PARA. Naproxen 1.5-3.0 μg/ml. The recovery study was found to be 97.91% for (PCM) and 98.64% for (NAX) accordingly. The projected technique was accurate, selective and precise for simultaneous assessment of NAP and PARA in bulk formulation.

![Fig. 6: Percentage Utility of Analytical Approaches used for estimation of Naproxen](ipimage)

*Tasnuva Haque et al. (2008)* reported that to simple, correct methods for the simultaneous estimation of NAP and RAN and their combined form of UV-Spectrophotometry method were studied and validated. Simultaneous equation technique (SEM) uses NAP and RAN inquiry using 313 nm in pH 7.4 phosphate buffer and 314 nm in 0.1N HCL and H2O as well as NAP investigation at 229 nm in pH 7.4 phosphate buffer and 232 nm in both 0.1N HCL and in H2O parallel to the specific absorption maxima. The tablet formulations were expected for the percent content of both the drugs at the designated wavelengths and the percent influence were 98.83 and 99.15 for NAP and RAN HCL respectively.
Table 7: Spectrophotometric methods used for determination of NAP alone and in combine dosage form

| S. No | Drugs          | Matrix              | Linearity (µg/ml) | Coefficient Correlation | Accuracy study in (%) | LOD&LOQ (µg/ml) | Ref |
|-------|----------------|---------------------|-------------------|-------------------------|-----------------------|-----------------|-----|
| 1     | NAP            | Bulk and Semi-solid Formulation | 10 - 60µg/ml     | 0.9984.                 | 80,100,120.           | LOD-1.5357µg/ml LOQ-5.1191µg/ml | 57  |
| 2     | NAP and PARA   | Bulk                | PARA-2.5 – 5.0µg/ml NAP 1.5 – 3.0µg/ml | PARA-0.9996 NAP-0.999 | 80, 100, 120. | - | 58  |
| 3     | NAP AND RAN-HCL | Tablet             | RAN-5-25µg/ml NAP-0.2-1.25 µg/ml | RAN-0.9976 NAP-0.997   | -                     | RAN-LOD-75.205 LOQ-250.685 NAP-LOD-1.411 LOQ-4.702 | 59  |
| 4     | NAP and DOM    | Tablet             | NAP-10-35 µg/ml DOM-5-30 µg/ml | NAP-0.9999 DOM-0.9998 | 80, 100, 120. | NAP-LOD 0.454 µg/ml DOM-LOD 0.657 mg/ml NAP-LOD 0.151 µg/ml DOM-2.18 mg/ml | 60  |
| 5     | NAP            | Tablet             | NAP-20-140 µg/ml | NAP-0.999               | 80,100,120.           | -               | 61  |
| 6     | LNP and NAP    | Tablet             | LAN-5-30µg/ml NAP-10-35µg/ml | LAN-(0.998) NAP-(0.999) | 80,100,120. | NAP-LOD 0.15µg/ml LAN-LOQ 1.7µg/ml NAP-LOD 0.04µg/ml LAN-LOD 0.5µg/ml | 62  |
| 7     | SUMA-S and NAP-S | Tablet         | 3-18 ppm for both the drugs. | -                   | 80, 100, 120. | LOD-NAP-0.24 SUM-0.31 LOQ NAP-0.74 SUM-0.94 | 63  |
| 8     | NAP and PAN    | -                  | NAP-10.0- 50.0 µg/ml PANTO-8.0- 18.0 µg/ml | NAP-0.998 PAN-0.996 | -                   | -               | 64  |
| 9     | NAP-S and PAN-S | Bulk and dosage form | NAP-02-10 µg/ml PAN-02-10 µg/ml | NAP-0.995 PAN-0.995 | NAP-80, 100, 120. | PAN-(6.4, 8, 9.6) NAP-0.011 µg/ml, 0.0042 µg/ml PAN-0.0042 µg/ml, 0.0129 µg/ml | 65  |
| 10    | ESOM and NAP   | Bulk and tablet dosage form | ESO-5-50µg/ml NAP-5-50µg/ml | ESO-0.9993 NAP-0.9995 | 80, 100, 120. | -               | 66  |

**Spectrofluorimetric methods**

Alberto Navalón et al. (1998) reported the different Spectrofluorimetry method, depend on measurement of native fluorescence intensity of both drugs at emission 300 nm and 520 nm is using excitation wavelength of 290 nm. The excitation–emission spectra of these compounds are powerfully overlapped, which doesn’t authorize their direct. The concentration range was discover to be 0.1-1.0µg/ml for NAP and 0.5-5.0 µg/ml for SA and 2.0-12.0 µg/ml for ASA. To validate the accurateness of the expected technique, the improved model, obtained by PLS-1, was useful to the purpose of these compounds in pharmaceuticals and human...
serum samples earlier spiked with dissimilar amounts of each chemical.\textsuperscript{57}

Patricia Damiani et al. (2002) defined a simple, sensitive and reliable Spectrofluorimetry technique for determination of Naproxen in tablets.

The fluorescence concentration was discovered to be 35 3 nm using an excitation frequency of 271 nm, and in order to validate the scheme the effects were contrasted with those acquired by the USP XXIV NF 19 Pharmacopoeia reference technique (HPLC). In this concluding case a modification process is necessary.\textsuperscript{68}

Liquid chromatography–mass spectrometric methods

Shanmugam Gopinath et al (2013) studied validated a simple fast method simultaneous analysis, in human plasma of NAP and ESOM using high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). Solid-phase extraction was used to obtain analyte and internal standard from human plasma, and differentiation of analyte and internal standard was accomplish on X Bridge C18 column using acetonitrile: ammonium formate in the ratio of (70:30 v/v). The calibration curve was linear from 3.00-700.02 \(\mu\)g/ml for esomeprazole and 0.50-150.08 for NAP, and Mass detection was obtained by ESI/MS/MS in destructive ion mode, checking at m/z 344.19! 194.12, 229.12! 169.05 And 205.13! 161.07 For ESOM, NAP and IS, respectively. The evaluate is suitable for measuring perfect esomeprazole and naproxen plasma concentrations in human bioequivalence study following combined paperwork.\textsuperscript{69}

Paul W. Elsinghorst et al. (2011) established a validated sensitive, accurate quantitative liquid chromatography-mass spectrometry (LC-MS/MS) technique for the purpose of NAP in human plasma was developed and absolutely validated permitting to present FDA and EMA guidelines. The LC-MS/MS scheme is the simultaneous accomplishment of great absolute recovery (90.0±3.6%), the LOD were search to be 0.100 g/mL, high inter-day precision (CV≤9.4%), high analytical recovery (between 94.4 and 103.1%). The linearity range was selected as 0.100–50.0 g/mL (r2 ≥0.998) combined with a short run time of only 2 min.\textsuperscript{70}

Capillary electrophoresis (CE) method

Pingping Zhang et al. (2018) Investigation of capillary electrophoresis coupling with chemiluminescence recognition scheme for influential naproxen was developed based on the improved chemiluminescence concentration of the luminol and K3Fe(CN)6 in alkaline solution. The disjuction was conducted in 30 m mol L-1 borate buffers at pH 10.0. The linearity range was selected as 10-2000 \(\mu\)g/ml, and LOD and LOQ was found to be 2.7 \(\mu\)g L-1 and 8.8 \(\mu\)g L-1, respectively. The proposed method was useful to identify NAP in human urine sample with acceptable analyse results.\textsuperscript{71}

Potentiometric methods

Ulku Dilek Uysal et al. (2004) This paper designates the potentiometric method to quantify naproxen in tablets. The solvent system composition of aqueous solution of 20% ethanol with an ionic capacity of 0.1 additional sodium chloride has been discover to be appropriate for naproxen examination. Similar solvent system was employed for titrant of 0.1 N HCl and to titrate the active material. Validation processes as repeatability (precision) (n=6) were calculated. It was found to be 0.70 for RSD% and 0.3 for ±CL (p<0.05). The analysis of 275 and 550 mg naproxen sodium tablets was carried out in the filtered and unfiltered tablet solutions for three successive days considering intra and inter-days. Precision values were in the range of 0.16-0.33 for unfiltered and 0.10-0.29 for filtered solutions and the amount of the tablets was found to be in the range of (103.0-108.7%) for unfiltered and (102.9-107.7%) for filtered solutions. The method proposed here is precise simple and rather cheap. Therefore, it is suggested for the routine analysis of naproxen sodium tablets.\textsuperscript{72}

Conclusion

The present review illustrates different analytical approaches exercised for the assessment of NAP. A frequent investigation had present including, Bio-analytical, HPLC, HPTLC, UV/Vis-Spectroscopy, Spectrofluorimetry, capillary electrophoresis, LC-MS, LC-ESI-MS etc. for estimation of NAP in bulk and in its combined pharmaceutical formulations and in plasma. Liquid chromatography with UV detection has been found to be most studied for estimation of NAP in bulk and pharmaceutical dosage forms, while hyphenated LS-MS, LS-MS/MS methods are reported for determination of NAP and its metabolite in plasma and other biological fluids. Further, methods were reported for its pharmacokinetic and bioequivalence studies. Few chromatography approaches like HPTLC and Stability-indicating HPLC and HPTLC are also reported in literature. Definite Spectrophometric methods in UV-Visible along with fluorimetric are mainly often used for estimation for NAP.

Abbreviations

NAP- Naproxen; ESOM-Esomeprazole; DOM-Domperidone; PARA-Paracetamol; PAN-Pantoprazole; RAN-Ranitidine; SUMA-Sumatriptan; \(\lambda_{\text{max}}\)-Wavelength Maxima; LIN-Linearity; FR-Flow Rate; RT-Retention Time; RF-Retention Factor; UV-VIS- UV/Visible Spectrophotometry; HPLC- High Performance Liquid Chromatography; RP-HPLC- Reverse Phase Liquid Chromatography; HPTLC- High Performance Thin Layer Chromatography; LC-MS/MS- Liquid Chromatography Mass Spectrometry/Mass Spectrometry; UPLC-MS/MS- Ultra Pressure Liquid Chromatography-Mass Spectrometry; ODS- Octadecyl silane; OPA- Orthophosphoric Acid; IUPAC- International Union of Pure and Applied Chemistry; IP-Indian Pharmacopoeia; Cm-Centimetre; mm-Millimetre; nm- Nanometre; \(\mu\)L- Micro
Litter; μg-Microgram; REF- Reference; DMF-Dimethylformamide; NaOH-Sodium Hydroxide; KOH-Potassium Hydroxide; ACN-Acetonitrile; MeOH-Methanol; EtOH-Ethanol; GAA –Glacial Acetic Acid; LOD – Limit of Detection; LOQ – Limit of Quantification.

Source of Funding
None.

Conflict of Interest
None.

Reference
1. Elsinghorst P.W., Kinzig M, Rodamer M, Holzgrabe U. and Sörgel F. An LC–MS/MS procedure for the quantification of naproxen in human plasma: Development, validation, comparison with other methods, and application to a pharmacokinetic study. J Chromatography B 2011;879(19):1686-96.
2. Muneer S, Muhammad I.N, Abrar M.A., Munir I. and Kaukab I. High Performance Liquid Chromatographic Determination of Naproxen in Prepared Pharmaceutical Dosage Form and Human Plasma and its Application to Pharmacokinetic Study. J Chromatogr Sep Tech 2017;8(369):2.
3. Filist M, Szlaska I, Kazza M. and Pawinski T. Validated HPLC-UV method for determination of naproxen in human plasma with proven selectivity against ibuprofen and paracetamol. Biomedical Chromatography 2016;30(6):953-61.
4. Mahaboob subhani. syed,2014. Analytical method development and validation for simultaneous estimation of naproxen and pantoprazole in capsule dosage Form by RP-HPLC. Int J Pharm Anal Res 2014;3(4):334-47.
5. Moyer S. Pharmacokinetics of Naproxen Sodium. Cephalalgia 1986;6(4):77-80.
6. Haque A, Amrohi SH, Nasare M, P Kumar.K, Pradeep Kumar.T, Nivedita.G et al, Analytical method development and validation for the estimation of naproxen using RP-HPLC. IOSR J Pharm 2012;2(4):19-24.
7. Andersen J.V. and Hansen S.H. Simultaneous quantitative determination of naproxen, its metabolite 6-O-desmethylnaproxen and their five conjugates in plasma and urine samples by high-performance liquid chromatography on dynamically modified silica. J Chromatography B: Biomed Sci Appl 1992;577(2):325-33.
8. Shirkhedkar A.A, Chauhdari S.R, Patil A.S. and Surana S.J. A Concise Review on Analytical Profile of Valsartan. Eurasian J Anal Chem 2017;12(4):337-64.
9. Pharmacopoeia-Volume III, I. (2010). Published by Indian Pharmacopoeial Commission for Ministry of Health and Family Welfare, Ghaziabad, New Delhi, pp.204, 593, 2695.
10. Shirkhedkar A.A, Chauhdari S.R, Patil A.S. and Surana S.J. A Concise Review on Analytical Profile of Valsartan. Eurasian J Anal Chem 2017;12(4):337-64.
11. Kumar S.A, Deb Nath M, Rao J.S. and Sankar D.G. A new bioanalytical method development & validation for simultaneous estimation of esomeprazole and naproxen in human plasma by using RP-HPLC. Br J Pharm Res 2014;4(19):2312.
12. Yilmaz B, Asci A. and Erdem A.F. HPLC method for naproxen determination in human plasma and its application to a pharmacokinetic study in Turkey. J Chromatogr Sci 2013;52(7):584-9.
13. Muneer S, Muhammad I.N, Abrar M.A., Munir I. and Kaukab I. High Performance Liquid Chromatographic Determination of Naproxen in Prepared Pharmaceutical Dosage Form and Human Plasma and its Application to Pharmacokinetic Study. J Chromatogr Sep Tech 2017;8(369):2.
14. Filist M, Szlaska I, Kazza M. and Pawinski T. Validated HPLC-UV method for determination of naproxen in human plasma with proven selectivity against ibuprofen and paracetamol. Biomed Chromatography 2016;30(6):953-61.
15. Shannugam G, Kumar R.S, Shankar M.B, Danabal P. Development and validation of a sensitive and high-throughput LC-MS/MS method for the simultaneous determination of esomeprazole and naproxen in human plasma. Biomed Chromatography 2013;27:894-9.
16. Sultana N, Arayne M.S. and Iftikhar B. Simultaneous Determination of Atenolol, Rosuvastatin, Spironolactone, Glitazolamide and Naproxen Sodium in Pharmaceutical Formulations and Human Plasma by RP-HPLC. J Chin Chem Soc 2008;55(5). pp.1022-1029.
17. Sun Y, Zhang Z, Xi Z. and Shi Z. Determination of naproxen in human urine by high-performance liquid chromatography with direct electrogenerated chemiluminescence detection. Talanta 2009;79(3):676-80.
18. Kumar, S.A., Deb Nath, M., Rao, J.S. and Sankar, D.G. A New Bioanalytical Method Development & Validation for Simultaneous Estimation of Esomeprazole and Naproxen in Human Plasma by Using RP-HPLC. Br J Pharm Res 2014;4(19):2312.
19. Sahoo N.K, Sahu M, Rao P.S. and Ghosh G. Development and Validation of Liquid Chromatography-Mass Spectroscopy/Mass Spectroscopy Method for Quantitative Analysis of Naproxen in Human Plasma after Liquid-Liquid Extraction. Tropical J Pharm Res 2014;13(9):1503-10.
20. Elsinghorst P.W., Kinzig M, Rodamer M, Holzgrabe U. and Sörgel F. An LC–MS/MS procedure for the quantification of naproxen in human plasma: Development, validation, comparison with other methods, and application to a pharmacokinetic study. J Chromatography B 2011;879(19):1686-96.
21. Keyhanian F, Alizadeh N. and Shojaaie A. Spectrophotometric determination of Naproxen as ion-pair with bromophenol blue in bulk, pharmaceutical preparation and human serum samples. Curr Chem Let 2014;3(1):15-22.
22. Solanki S.D. and Patel P.U.. Development and validation of reversed-phase high performance liquid chromatographic method for simultaneous estimation of sumatriptan succinate and naproxen sodium in pharmaceutical dosage form. Int J Pharm Pharm Sci 2012;4(1):276-8.
23. Mondal M.S, Haque M.A, Islam M.S. and Islam S.A. Development and validation of RP-HPLC method for the simultaneous estimation of domperidone and naproxen in tablet dosage form. J Appl Pharm Sci 2011;1(7):145.
24. Haque A, Amrohi SH, Nasare M, P Kumar.K, P Kumar.T, Nivedita.G et al, Analytical method development and validation for the estimation of naproxen using RP-HPLC. IOSR J Pharm 2012;2(4):19-24.
25. Mehta P, Sharma C.S, Nikam D. and Ranawat M.S. Development and validation of related substances method by HPLC for analysis of naproxen in naproxen tablet formulations. Int J Pharm Sci Drug Res 2012;4(1):63-9.
26. Tsvetkova, B. RP-HPLC method for determination of naproxen in Pharmaceutical dosage form. PHARMACIA, 2015;52(3):15-9.
27. Kumar S.A, Deb Nath M. and Kumar V.P.K, 2016. Method development and validation for estimation of Naproxen in bulk samples as well as in tablet dosage forms by using RP-HPLC. Pharma Tutor 2016;4(9):33-9.
28. Rao K.T. and Rao L.V. A validated stability-indicating UHPLC method for determination of naproxen and its related
chamotographic method for simultaneous estimation of sumatranitum succinate and naproxen sodium in pharmaceutical dosage form. Int J Pharm Pharm Sci 2012;4(1):276-8.

30. Razzaq S.N, Ashfaq M, Khan L.U. and Mariam I. Development and validation of liquid chromatographic method for naproxen and esomeprazole in binary combination. J Chilean Chemical Soc 2012;57(4):1456-9.

31. Mondal M.S, Haque, M.A, Islam M.S. and Islam S.A, Development and validation of RP-HPLC method for the simultaneous estimation of domperidone and naproxen in tablet dosage form. J Appl Pharm Sci 2011;1(7):145.

32. Shekhar C.E, Kumar R.S, Hank R.M. and Prasanti P. Simultaneous Estimation of Naproxen Sodium and Domperidone Maleate in Bulk and Pharmaceutical Dosage Form by Modified RP-HPLC Method. Int J Pharm Chemical Sci 2012;1(4).

33. Vani P. and Kottapalli K.S. Development and validation of RP-HPLC method for simultaneous estimation of naproxen and esomeprazole in pharmaceutical dosage form. Int J Pharm Technol, 2011;3:3446-55.

34. Debnath M, Kumar S.A, Anguluri D.P, Sri G.P, Ramya J.V.L.N. and Sankar D.G et al, An analytical method development and validation for simultaneous estimation of Sumatriptan and Naproxen in bulk samples as well as in tablet dosage forms by using RP-HPLC.

35. Mohideen S, Shivakath M, SureshKumar P, Krishnan S.N, Surendranath Y. and Satyanarayana T. Development and validation of analytical method for naproxen and pantoprazole in capsule dosage form. Der Pharm Sinica, 2011;2(6):114-21.

36. M subhani, syed, Analytical method development and validation for simultaneous estimation of naproxen and pantoprazole in capsule dosage form by RP-HPLC. Int J Pharm Anal Res 2011;3(4):334-7.

37. Jain D.K, Jain N, Charde R. and Jain N. The RP-HPLC method for simultaneous estimation of esomeprazole and naproxen in binary combination. Pharm Method 2011;2(3):167-72.

38. Bhuyan, M.H.U., Development and validation of method for determination of esomeprazole and naproxen from clobination product by HPLC.

39. Reddy P.S, Sait S, Vasudeurmuthy G, Vishwanath B, Prasad V. and Reddy S.J. Stability indicating simultaneous estimation of assay method for naproxen and esomeprazole in pharmaceutical formulations by RP-HPLC. Der Pharma Chemica 2011;3(6):553-64.

40. Khan M.F, Zuthi S.S, Kayser M.S, Islam M.S, Asad S. and Rashid M.A, A Simple RP-HPLC Method Development and Validation for the Simultaneous Estimation of Naproxen and Rabeprazole. J Appl Pharm Sci 2016;6(11):147-52.

41. Vasanthi R, Sumathi B, M Alagar Raja, V. Shrishaa, Banji D, Kumar DS. Analytical method development and validation for the simultaneous estimation of sumatranitum and naproxen in bulk and pharmaceutical dosage form by RP-HPLC. Asian J Pharm Anal Med Chem 2015;3(3):137-44.

42. Ekpe A, Tong J.H. and Rodriguez L. High-performance liquid chromatographic method development and validation for the simultaneous quantitation of naproxen sodium and pseudoephedrine hydrochloride impurities. J Chromatographic Sci 2001;39(3):381-6.

43. Gondalia R. and Dharamsi A. Simultaneous estimation of sumatranitum succinate and naproxen sodium in bulk drug and pharmaceutical dosage form by RP-HPLC method. J Drug Delivery Ther 2013;3(2).

44. Reddy Y.R, Kumar K.K, Reddy M.R.P. and Mukkanti K, Rapid simultaneous determination of sumatranitum succinate and naproxen sodium in combined tablets by validated ultra-performance liquid chromatographic method. J Anal Bioanalytical Tech 2011;2(3):1-6.

45. Singh K.B, Waiker S.B. and Padmane S.P, A validated RP-HPLC method for the simultaneous estimation of paracetamol and naproxen in tablet formulation. Int J Pharm Sci Res 2011;3(11):4270.

46. Kumar S.A, Debnath M. and Rao J.S. Simultaneous estimation of Esomeprazole and Naproxen in bulk as well as in pharmaceutical formulations by using RP-HPLC. Int J Pharm Sci Res 2013;4(8):2988.

47. Wahbi, A.A.M, Mabrouk, M.M., Moneeb, M.S. and Kamal, A.H., 2009. Simultaneous determination of the two non-steroidal anti-inflammatory drugs; diflunisal and naproxen in their tablets by chemometric spectrophotometry and HPLC. Pak J Pharm Sci 22(1).

48. Haque M.A, Shahriar M, Parvin M.N. and Islam S.A, Validated RP-HPLC method for estimation of ranitidine hydrochloride, domperidone and naproxen in solid dosage form. Asian J Anal Chem 2011;3:59-63.

49. Dirıc E, Özdemir A, Aksoy H, Üstündag Ö. and Baleanu D. Chemometric determination of naproxen sodium and pseudoephedrine hydrochloride in tablets by HPLC. Chem Pharm Bull 2006;54(4):415-21.

50. Kayesh R. and Sultan M.Z. A novel ion-pair RP-HPLC method for simultaneous quantification of naproxen and esomeprazole in pharmaceutical formulations. J Chromatographic Sci 2014;53(5):687-93.

51. SV. D., Mahaparale, S., Shinde, S. and Funne, S., Development and Validation of Esomeprazole and Naproxen in Bulk and Tablet Dosage Form by RP-HPLC Method. Dev 2(5).

52. Nalluri B.N, Murdula B, Chitraalatha K, Sultana S.A. and Chandra, T.U. Development of stability indicating RP-HPLC-PDA method for the simultaneous analysis of naproxen sodium and diphenhydramine hydrochloride in bulk and tablet dosage forms. Indian Drugs 2015;52(9):9.

53. Gondalia R. and Dharamsi A. HPTLC method for simultaneous determination of Naproxen sodium and Sumatriptan succinate in pharmaceutical dosage form. Int J Pharm Sci Res 2011;2(1):130-4.

54. Pawar S.M, Patil B.S. and Chaudhari R.Y. Validated HPTLC method for simultaneous quantitation of domperidone maleate and naproxen sodium in bulk drug and formulation. Eurasian J Anal Chem 2010;5(3):284-92.

55. Patil A. and Mulia S. Development and Validation of HPTLC Method for the Simultaneous Estimation of Naproxen and Pantoprazole in Combined Dosage Form. Int J Pharm Pharm Sci 2013;5:222-225.

56. Bhole R.P, Shinde S.S., Chitlange S.S. and Wankhede S.B. A high-performance thin layer chromatography (HPTLC) method for simultaneous determination of diphenhydramine hydrochloride and naproxen sodium in tablets. An Alytical Chem Insights 2015;10:ACI-31506.

57. Dharmalingam S.R, Ramamurthy S, Chidambaram K. and Nadaraja S. Development and validation of UV spectrophotometric method for the estimation of naproxen in bulk and semi-solid formulation. Int J Anal Pharm Biomed Sci 2013;2:49-55.

58. Patel A., Firke S.D., Bari S.B. and Ranoliya J.R,. Development and Validation of UV-Spectrophotometric Method for Simultaneous Estimation of Naproxen and Paracetamol by Q-Absorbance Ratio Method. Int J Pharm Res Allied Sci 2014;3:57-63.
59. Haque T, Talukder M.M.U, Laila S, Fatema K. and Kabir A.K.L. Simultaneous estimation of naproxen and ranitidine HCl by using UV spectrophotometer. *Stamford J Pharm Sci* 2008;1(1):18-24.

60. Singh S, Sharma S, Yadav A.K. and Gautam H.. Simultaneous Estimation of Naproxen and Domperidone Using UV-spectrophotometry in Tablet Dosage Form. *Bull Pharm Res* 2013;3(2):66-70.

61. AD P.K., Sunita G., Venkata Raju Y, Rama Krishna K, Swathi B., Praveen C.H et al. Novel spectrophotometric estimation of Naproxen Tablet formulations using sodium citrate as hydrotropic solubilizing agent. *Asian J Res Chem* 2011;4(5):845-7.

62. Choudhary N, Siddiqui I, Rai J, Singh S, Surabhi S. and Gautam H. Simultaneous Estimation of Lansoprazole and Naproxen Using UV-spectrophotometry in Tablet Dosage Form. *Bull Pharm Res* 2013;3(2):66-70.

63. Navalón A, Blanc R, del Olmo, M. and Vilchez J.L.. Simultaneous determination of naproxen, salicylic acid and acetylsalicylic acid by spectrophotometry using partial least-squares (PLS) multivariate calibration. *Talanta*, 1999;48(2):469-75.

64. Damiani P, Bearzotti M. and Cabezón M.A. Spectrofluorometric determination of naproxen in tablets. *Journal of Pharmaceutical and Biomedical Analysis*, 2002;29(1-2):229-38.

65. Shanmugam G., Kumar R.S, Shankar M.B, Danabal P, Development and validation of a sensitive and high-throughput LC-MS/MS method for the simultaneous determination of esomeprazole and naproxen in human plasma. *Biomedical Chromatography* 2013;27:894-9.

66. Zhang, Sun Y, Xue H, Wang X, Lian K. Determination of naproxen in human urine by capillary electrophoresis with chemiluminescence detection. *Global Drugs Ther* 2018;3(5):1-5.

67. Elsinghorst, P.W., Kinzig, M., Rodamer, M., Holzgrabe U. and Sörgel F, An LC–MS/MS procedure for the quantification of naproxen in human plasma: Development, validation, comparison with other methods, and application to a pharmacokinetic study. *Journal of Chromatography B*, 2011;879(19):1686-96.

68. Uysal Ü.D. and Tunçel M, Determination of naproxen in tablets by using first derivative potentiometry. *Prostaglandins* 2004;1:2.

**How to cite this article:** Jain P. A concise review on analytical profile of naproxen. *Int J Comprehensive Adv Pharmacol* 2019;4(3):70-81.